Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2‑positive breast cancer.

ABSTRACT: Despite advances in HER2‑targeted therapy for HER2‑positive breast cancer, resistance to trastuzumab and tumor recurrence remain major barriers to durable outcomes. The present study evaluated the therapeutic potential of ebastine, a second‑generation H1‑antihistamine, as a repurposing candidate to overcome trastuzumab resistance by targeting HER2 signaling and cancer stem cell (CSC)‑associated phenotypes in HER2‑positive breast cancer cells. Molecular docking studies revealed that ebastine bound to the ATP‑binding site of the HER2 tyrosine kinase domain, thereby suppressing the phosphorylation of HER2, p95HER2 and HER3, as assessed by immunoblotting. Immunoprecipitation assay further demonstrated that this binding disrupted HER2/HER3 and HER2/EGFR heterodimerization, leading to reduced do

SUBMITTER: Jung E 

PROVIDER: S-EPMC12871574 | biostudies-literature | 2026 Apr

REPOSITORIES: biostudies-literature